Compare DXC & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DXC | SUPN |
|---|---|---|
| Founded | 1959 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | N/A | 2012 |
| Metric | DXC | SUPN |
|---|---|---|
| Price | $14.16 | $45.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $15.33 | ★ $63.25 |
| AVG Volume (30 Days) | ★ 2.0M | 782.6K |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1492.90 | N/A |
| EPS | ★ 2.03 | N/A |
| Revenue | ★ $12,714,000,000.00 | $681,539,000.00 |
| Revenue This Year | N/A | $8.32 |
| Revenue Next Year | N/A | $23.36 |
| P/E Ratio | $6.96 | ★ N/A |
| Revenue Growth | N/A | ★ 4.54 |
| 52 Week Low | $11.82 | $29.16 |
| 52 Week High | $23.75 | $57.65 |
| Indicator | DXC | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 63.44 | 46.31 |
| Support Level | $11.82 | $44.09 |
| Resistance Level | $12.87 | $47.00 |
| Average True Range (ATR) | 0.38 | 1.25 |
| MACD | 0.17 | 0.10 |
| Stochastic Oscillator | 95.33 | 57.97 |
DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.